Arecor successfully defends a key Europan Polysaccharide Vaccine Patent in its opposition proceedings

The successfully defended patent protects novel compositions of a specific type and group of vaccines, called polysaccharide vaccines. Examples of polysaccharide vaccines are vaccines that are used to protect against Meningitis or Pneumonia. Such products are known to degrade over time, leading to gradual loss of potency. The novel compositions protected by this patent prevent such degradation and enable the development of improved polysaccharide vaccines in more convenient dosage forms that can be used outside the cold chain, thereby increasing the efficiency of immunisation coverage.

Arecor’s proprietary formulation technology, Arestat™, enables unparalleled biopharmaceutical product profiles across a broad range of therapies, including liquid vaccine compositions with improved stability. Arecor partners with leading pharmaceutical and biotech companies to deliver unequalled reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

The Company has invested considerably into building a strong patent portfolio to protect the Arestat™ technology as well as the product assets that it enables. Arecor’s intellectual property portfolio currently comprises 25 patent families, within which 26 individual patents have been granted in key territories.

European patents can be opposed by other companies within a certain period of time following their formal grant. The ensuing opposition process follows strictly defined rules and can result in the patent being revoked, amended or upheld in the original form.
The Company’s European patent on polysaccharide vaccines had recently been opposed and the two years of opposition process culminated in oral proceedings at the Opposition Division of the European Patent Office. The decision of the Opposition Division was favourable to Arecor and the patent was upheld with no amendments.

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “We are delighted about the successful outcome of the opposition proceedings. Having developed a highly innovative formulation technology, Arecor has established itself firmly as a world leader in the formulation of superior biopharmaceuticals and vaccines. However, the value of our technology would be significantly diminished without strong patent protection, which is why we have been systematically building a complex patent portfolio around our technology and product assets. Our success in the opposition proceedings is great news for Arecor, as it demonstrates the value and the strength of our innovative formulation science and associated intellectual property. Polysaccharide vaccines represent a very important class of vaccines for preventing infections such as meningitis or pneumonia. Our proprietary compositions permit formulating such vaccines in a way that simplifies their administration to patients.”

About Arecor and its Arestat™ technology
Arecor Limited is a technology leader in developing superior liquid formulations of biopharmaceuticals through the application of its proprietary innovative formulation technology platform: Arestat™. Using the platform, Arecor has an excellent track record in delivering highly differentiated formulations of protein- and peptide-based pharmaceuticals as well as many vaccines.

Arecor partners with leading pharmaceutical and biotech companies to deliver superior formulations of their exclusive products, across novel products’ pipelines, biosimilars and in lifecycle management. As such, Arecor successfully develops differentiated product profiles, including stable high-concentration biologics with low viscosity and reformulations of lyophilised or freeze-dried products into stable liquids biopharmaceuticals that can be used outside the cold chain. Furthermore, Arecor is leveraging this platform to develop its own proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Currently such portfolio includes:
• Stable aqueous glucagon for emergency and artificial pancreas use,
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and,
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices and,
• A series of undisclosed pre-clinical programmes.

About Arecor’s Patent Portfolio
Arecor’s technology is protected by 25 patent families, including 26 granted patents.

For more information, please contact:

Dr Laura AS Ciccolini, Director of Business Development and Licensing
Arecor Limited
Tel: +44 (0) 1223 426 060
Mob: +44 (0) 7900 784 220
Email: laura.ciccolini@arecor.com

Mr Tarquin Edwards
Peckwater PR
Mo: +44 (0) 7879 458 364
Email: tarquin.edwards@peckwaterpr.co.uk
 

More within